Integra Lifesciences (NASDAQ: IART) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

87.6% of Integra Lifesciences shares are owned by institutional investors. Comparatively, 96.5% of DENTSPLY SIRONA shares are owned by institutional investors. 21.5% of Integra Lifesciences shares are owned by insiders. Comparatively, 2.0% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Integra Lifesciences and DENTSPLY SIRONA, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra Lifesciences 0 7 3 0 2.30
DENTSPLY SIRONA 1 3 8 0 2.58

Integra Lifesciences currently has a consensus target price of $51.88, suggesting a potential downside of 3.02%. DENTSPLY SIRONA has a consensus target price of $69.82, suggesting a potential upside of 12.65%. Given DENTSPLY SIRONA’s stronger consensus rating and higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Integra Lifesciences.

Earnings & Valuation

This table compares Integra Lifesciences and DENTSPLY SIRONA’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Integra Lifesciences $992.08 million 4.23 $74.56 million $0.61 87.69
DENTSPLY SIRONA $3.75 billion 3.80 $429.90 million ($3.48) -17.81

DENTSPLY SIRONA has higher revenue and earnings than Integra Lifesciences. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.


DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Integra Lifesciences does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.


This table compares Integra Lifesciences and DENTSPLY SIRONA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra Lifesciences 4.52% 16.35% 6.83%
DENTSPLY SIRONA -20.33% 7.56% 5.18%

Risk & Volatility

Integra Lifesciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.


DENTSPLY SIRONA beats Integra Lifesciences on 9 of the 16 factors compared between the two stocks.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.


DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with's FREE daily email newsletter.